Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study Publication Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…Danielle Pillsbury2025 年 3 月 20 日
Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling Video Certara Phoenix 平台 — 全球最值得信赖的药代动力学/药效学(PK/PD)分析与建模平台 Today's drug candidates are more complex than ever. But with development decisions on the line,…Danielle Pillsbury2025 年 2 月 12 日
Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease Poster 利用模拟结果为探索全人源抗 IL-6 抗体 TOUR006 治疗甲状腺眼病的 IIb 期试验确定剂量 Danielle Pillsbury2025 年 2 月 7 日
Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies Publication 针对复发难治性(R/R)骨髓纤维化(MF)及其他髓系或实体瘤恶性肿瘤患者的 Navtemadlin 群体药代动力学与药效学分析 This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…Danielle Pillsbury2025 年 2 月 6 日
Advancing pharmacometrics in Africa – Transition from capacity development toward job creation Publication 推动非洲定量药理学的发展 — 从能力建设向创造就业过渡 This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…Danielle Pillsbury2024 年 12 月 9 日
Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi Poster GalNAc-siRNA 偶联物 Plozasiran(ARO-APOC3)治疗严重高甘油三酯血症患者的群体药代动力学-药效学(K-PD)建模 Danielle Pillsbury2024 年 11 月 22 日
健康受试者中TBA-7371的群体药代动力学建模揭示了清除率的表观自身诱导现象,并预测了结核分枝杆菌感染受试者的药代动力学 海报 健康受试者中TBA-7371的群体药代动力学建模揭示了清除率的表观自身诱导现象,并预测了结核分枝杆菌感染受试者的药代动力学 Danielle Pillsbury2024 年 11 月 22 日
Impacts of dose titration on logistic exposure-response in simulated flexible-dose clinical trials Poster 剂量滴定对模拟灵活剂量临床试验中逻辑暴露-反应关系的影响 Danielle Pillsbury2024 年 11 月 22 日
Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma Poster 复发/难治性多发性骨髓瘤患者 Belantamab Mafodotin、可溶性B细胞成熟抗原(BCMA)和血清 M-蛋白的群体药代动力学-药效学(PKPD)同步分析 Danielle Pillsbury2024 年 11 月 22 日
A Pharmacokinetic Analysis of Drug Concentration Using a Novel Deep Learning Model Poster 利用新型深度学习模型进行药物浓度的药代动力学分析 Danielle Pillsbury2024 年 11 月 22 日